Reagent substitutions in the Centers for Disease Control and Prevention Nijmegen‐Bethesda assay for factor VIII inhibitors
- 24 March 2018
- journal article
- letter
- Published by Wiley in Haemophilia
- Vol. 24 (3) , e116-e119
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Limit of detection and threshold for positivity of the Centers for Disease Control and Prevention assay for factor VIII inhibitorsJournal of Thrombosis and Haemostasis, 2017
- Definitions in hemophilia: communication from the SSC of the ISTHJournal of Thrombosis and Haemostasis, 2014
- Does the presence of von Willebrand factor in FVIII‐deficient plasma influences the measurement of FVIII inhibitor titres in haemophilia A patients?International Journal of Laboratory Hematology, 2014
- Validation of 4% albumin as a diluent in the Bethesda Assay for FVIII inhibitorsThrombosis Research, 2013
- Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patientsBlood, 2013
- Validation of Nijmegen–Bethesda assay modifications to allow inhibitor measurement during replacement therapy and facilitate inhibitor surveillanceJournal of Thrombosis and Haemostasis, 2012
- Laboratory Assessment of Factor VIII Inhibitor TiterAmerican Journal of Clinical Pathology, 2009
- A 4% solution of bovine serum albumin may be used in place of factor VIII:C deficient plasma in the control sample in the Nijmegen Modification of the Bethesda factor VIII:C inhibitor assay.2002
- The type of factor VIII deficient plasma used influences the performance of the Nijmegen modification of the Bethesda assay for factor VIII inhibitors.2001
- The Nijmegen Modification of the Bethesda Assay for Factor VIII:C Inhibitors: Improved Specificity and ReliabilityThrombosis and Haemostasis, 1995